Vascular Stock Analysis

VBLT Stock  USD 0.22  0.01  4.35%   
The main objective of Vascular Biogenics stock analysis is to determine its intrinsic value, which is an estimate of what Vascular Biogenics is worth, separate from its market price. There are two main types of Vascular Biogenics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Vascular Biogenics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Vascular Biogenics' stock to identify patterns and trends that may indicate its future price movements.
The Vascular Biogenics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vascular Biogenics is usually not traded on Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Veterans Day ( substitute day ), Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday. Vascular Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vascular Biogenics' ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vascular Biogenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Vascular Stock please use our How to Invest in Vascular Biogenics guide.

Vascular Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.2. The entity had not issued any dividends in recent years. Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. For more information please call Dror Harats at 972 8 993 5000 or visit

Vascular Biogenics Quarterly Cost of Revenue


Vascular Biogenics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vascular Biogenics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vascular Biogenics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vascular Biogenics generated a negative expected return over the last 90 days
Vascular Biogenics has high historical volatility and very poor performance
Vascular Biogenics has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K.
Vascular Biogenics currently holds about 34.15 M in cash with (31.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Vascular Biogenics has a frail financial position based on the latest SEC disclosures
Roughly 13.0% of the company outstanding shares are owned by insiders
Latest headline from VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

Vascular Biogenics Upcoming and Recent Events

Earnings reports are used by Vascular Biogenics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vascular Biogenics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of November 2023
Upcoming Quarterly Report
30th of September 2023
Next Fiscal Quarter End

Vascular Biogenics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Vascular Biogenics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Vascular Biogenics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Vascular Biogenics specific information freely available to individual and institutional investors to make a timely investment decision.
6th of September 2023
Financial Statements and Exhibits. Other Events
1st of September 2023
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
14th of August 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
15th of May 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of March 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
9th of March 2023
Completion of Acquisition or Disposition of Assets
1st of March 2023
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
23rd of February 2023
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets

Vascular Biogenics Thematic Classifications

In addition to having Vascular Biogenics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Vascular Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vascular Biogenics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vascular Biogenics backward and forwards among themselves. Vascular Biogenics' institutional investor refers to the entity that pools money to purchase Vascular Biogenics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Morgan Stanley2023-06-30Common Shares327 K75.2 K
Telemetry Investments Llc2022-12-31Common Shares403.5 K48 K
Acadian Asset Management Llc2022-12-31Common Shares280.2 K33 K
Renaissance Technologies Llc2022-12-31Common Shares264.5 K32 K
Group One Trading Lp2023-06-30Common Shares127.3 K29.3 K
Virtu Financial Llc2023-06-30Common Shares79.9 K18 K
Citadel Advisors Llc2022-12-31Common Shares128.3 K15.4 K
Lpl Financial Llc2022-12-31Common Shares88.9 K10.7 K
Two Sigma Securities Llc2022-09-30Common Shares62.2 K10 K
Geode Capital Management Llc2023-06-30Common Shares40.3 K9.3 K
Catalyst Financial Partners Llc2023-06-30Common Shares39 KK
Note, although Vascular Biogenics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vascular Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vascular Biogenics's market, we take the total number of its shares issued and multiply it by Vascular Biogenics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vascular Profitablity

Vascular Biogenics' profitability indicators refer to fundamental financial ratios that showcase Vascular Biogenics' ability to generate income relative to its revenue or operating costs. If, let's say, Vascular Biogenics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vascular Biogenics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vascular Biogenics' profitability requires more research than a typical breakdown of Vascular Biogenics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Average Assets(0.78)(0.83)
Return on Average Equity(1.03)(1.06)
Return on Invested Capital(1.81)(1.95)
Return on Sales(48.97)(52.83)

Management Efficiency

Vascular Biogenics has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.83 in 2023. Return on Average Equity is likely to drop to -1.06 in 2023. Total Liabilities is likely to gain to about 8 M in 2023. Current Liabilities is likely to gain to about 6.9 M in 2023
Last ReportedProjected for 2023
Book Value per Share 0.29  0.29 
Enterprise Value over EBIT(3.45)(3.72)
Enterprise Value over EBITDA 0.29  0.32 
Price to Book Value 0.37  0.38 
Tangible Assets Book Value per Share 0.38  0.39 
Enterprise Value-9.2 M-9.4 M
Tangible Asset Value29.7 M40 M
The analysis of Vascular Biogenics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vascular Biogenics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vascular Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Short Long Term Debt Total
564 K
Income Tax Expense
-85 K
Interest Expense
85 K
Total Operating Expenses
33.4 M
Other Operating Expenses
33.5 M

Technical Drivers

As of the 21st of September, Vascular Biogenics has the Coefficient Of Variation of 44185.5, risk adjusted performance of 0.0102, and Semi Deviation of 4.41. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vascular Biogenics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Vascular Biogenics, which can be compared to its competition. Please validate Vascular Biogenics jensen alpha and semi variance to decide if Vascular Biogenics is priced more or less accurately, providing market reflects its prevalent price of 0.22 per share. As Vascular Biogenics appears to be a penny stock we also recommend to double-check its total risk alpha numbers.

Vascular Biogenics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vascular Biogenics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vascular Biogenics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Vascular Biogenics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vascular Biogenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vascular Biogenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vascular Biogenics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vascular Biogenics Technical and Predictive Indicators

Vascular Biogenics Forecast Models

Vascular Biogenics' time-series forecasting models are one of many Vascular Biogenics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vascular Biogenics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Vascular Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vascular Biogenics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vascular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vascular Biogenics. By using and applying Vascular Stock analysis, traders can create a robust methodology for identifying Vascular entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(47.36)(48.60)
Gross Margin 0.84  0.73 
Profit Margin(49.09)(52.97)

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Vascular Biogenics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Share Portfolio Now


Share Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vascular Biogenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Vascular Stock please use our How to Invest in Vascular Biogenics guide. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Vascular Stock analysis

When running Vascular Biogenics' price analysis, check to measure Vascular Biogenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vascular Biogenics is operating at the current time. Most of Vascular Biogenics' value examination focuses on studying past and present price action to predict the probability of Vascular Biogenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vascular Biogenics' price. Additionally, you may evaluate how the addition of Vascular Biogenics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Correlations
Find global opportunities by holding instruments from different markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Vascular Biogenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vascular Biogenics. If investors know Vascular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vascular Biogenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Vascular Biogenics is measured differently than its book value, which is the value of Vascular that is recorded on the company's balance sheet. Investors also form their own opinion of Vascular Biogenics' value that differs from its market value or its book value, called intrinsic value, which is Vascular Biogenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vascular Biogenics' market value can be influenced by many factors that don't directly affect Vascular Biogenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vascular Biogenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vascular Biogenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vascular Biogenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.